Mayo Clinic experimental dual-drug nanotherapy crosses the blood-brain barrier and improved survival in preclinical glioblastoma models
Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, extending survival in preclinical glioblastoma models and highlighting a potential new strategy for treating one of the most aggressive forms of brain cancer.
Mayo Clinic researchers reported that a dual-drug nanotherapy crossed the blood-brain barrier, targeted glioblastoma tumors and improved survival in preclinical models, particularly when combined with radiation.
Date: April 8, 2026
Key facts
- Mayo Clinic researchers developed an experimental dual-drug nanotherapy for glioblastoma.
- The treatment was designed to cross the blood-brain barrier and deliver two cancer drugs directly to tumor cells.
- In preclinical models using patient-derived tissue, combining the nanotherapy with radiation more than doubled survival compared with untreated controls.
- Researchers are conducting additional safety and dosing studies before clinical trials can begin.
JACKSONVILLE, Fla. — Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, according to a study published in Nature Communications Medicine. The strategy extended survival in preclinical models of glioblastoma, the most aggressive form of brain cancer.
The nanotechnology-based approach packages two existing cancer drugs into tiny particles engineered to cross the brain’s protective blood-brain barrier and target tumor cells. In preclinical models using patient-derived tissue, combining the treatment with radiation more than doubled survival compared with untreated controls.
Dual-drug liposome strategy targets glioblastoma more precisely
Glioblastoma is notoriously difficult to treat. Patients typically survive for about 15 months after diagnosis, even with current standards of care such as surgery, radiation and chemotherapy. One of the biggest challenges is that many drugs cannot effectively reach tumors in the brain, and those that do often become less effective as tumors develop resistance.
The new approach uses small lipid-based particles, known as liposomes, to carry and deliver a combination of drugs — everolimus or rapamycin and vinorelbine — directly to cancer cells through a new tumor-targeting strategy. By ensuring both drugs reach the same cells at the same time, the researchers aim to improve tumor-killing effects while reducing the toxic side effects associated with higher drug doses.
“Glioblastoma remains extremely difficult to treat due to drug resistance and limited drug delivery to the brain,” said Debabrata (Dev) Mukhopadhyay, Ph.D., a professor of biochemistry and molecular biology at Mayo Clinic in Florida and a senior author of the study.
Dr. Mukhopadhyay said the approach is designed to improve both drug delivery and therapeutic impact by targeting the tumor directly and combining therapies in a way that enhances their effect. The drug combination includes agents that interfere with tumor growth pathways and disrupt the cancer’s ability to repair DNA damage, making tumors more sensitive to radiation.
Combination with radiation produced stronger survival benefit
The preclinical results suggest that the nanotherapy may be especially relevant as a combination strategy rather than as a standalone intervention. In the models studied, the treatment plus radiation generated a survival advantage that was substantially greater than no treatment, supporting the idea that improved drug delivery can amplify the effects of standard-of-care radiation in glioblastoma.
This matters because many glioblastoma therapies fail not only because of tumor biology, but because adequate concentrations of the drugs do not reach the tumor at the right time. A dual-delivery liposomal system may help address that problem by increasing coordinated exposure of tumor cells to both agents while also limiting broader systemic toxicity.
“This represents a promising direction for treating patients with glioblastoma and advancing new technologies and therapies, so we can one day improve the survival of patients with brain cancer by delivering novel cancer therapies to the brain,” said Alfredo Quinones-Hinojosa, M.D., a senior author on the study.
Researchers are preparing safety and dosing studies before clinical trials
Mayo Clinic said further research will be needed to determine whether the preclinical findings translate to patients. Researchers are now conducting additional safety and dosing studies required before clinical trials can begin. If successful, the approach could eventually be developed as an oral or intravenous therapy used alongside standard treatment or as an option for patients whose tumors do not respond to currently available therapies.
Dr. Mukhopadhyay said that while the work is still in development, it represents an important step toward more precise cancer treatments that are both more effective and less toxic, with the potential to improve quality of life for patients. The study was supported in part by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number R01NS129671.
Mayo Clinic positions the research within broader cancer innovation efforts
Mayo Clinic described itself as a nonprofit organization committed to innovation in clinical practice, education and research. Its Comprehensive Cancer Center, designated by the National Cancer Institute as a comprehensive cancer center, said it is focused on patient-centered cancer care and on research breakthroughs in cancer detection, prevention and treatment.
Taken together, the glioblastoma nanotherapy study points to a broader translational goal: to use advanced delivery systems to overcome the blood-brain barrier, reduce resistance-related failure and create treatment combinations that may eventually improve outcomes in one of oncology’s most difficult diseases. While the work remains preclinical, the survival signal and the barrier-crossing design give the program clear scientific and clinical relevance.
